Updated results of the PATH study: Adjuvant therapy with donafenib plus a PD-1 inhibitor for patients with hepatocellular carcinoma at high risk of recurrence after resection

被引：0
|
作者：
Chen, Yiwen [1 ]
Shen, Yan [1 ]
Zhang, Min [1 ]
Wu, Jian [1 ]
Gao, Shunliang [1 ]
Que, Risheng [1 ]
Yu, Jun [1 ]
Tang, Xiaofeng [1 ]
Bai, Xueli [1 ]
Liang, Tingbo [1 ]
机构：
[1] Zhejiang Univ, Sch Med, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.571
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：571 / 571
页数：1
相关论文
共 50 条
  • [21] Preliminary results of ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after radical resection
    Mao, Xianhai
    Duan, Xiaohui
    Wu, Dongde
    Zhou, Cuncai
    Tian, Yifeng
    Shen, Jian
    Xu, Guohui
    Lai, Jianlin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 494 - 494
  • [22] Update results of ALTER-H006: A phase II study of TQB2450 plus anlotinib as adjuvant therapy in hepatocellular carcinoma (HCC) with high risk of recurrence after surgical resection
    Mao, X.
    Duan, X.
    Wu, D.
    Zhou, C.
    Tian, Y.
    Shen, J.
    Xu, G.
    Bai, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S658 - S658
  • [23] PD-1 inhibitors plus lenvatinib versus PD-1 inhibitors plus regorafenib in patients with advanced hepatocellular carcinoma after failure of sorafenib
    Xu, Yongkang
    Fu, Shumin
    Shang, Kai
    Zeng, Jiayu
    Mao, Ye
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [24] Neoadjuvant transarterial chemoembolization (TACE) plus PD-1 inhibitor bridging to tumor resection in intermediate-stage hepatocellular carcinoma patients
    Zhu, Caihua
    Dai, Bing
    Zhan, Hua
    Deng, Ruoyu
    IRISH JOURNAL OF MEDICAL SCIENCE, 2023, 192 (03) : 1065 - 1071
  • [25] Neoadjuvant transarterial chemoembolization (TACE) plus PD-1 inhibitor bridging to tumor resection in intermediate-stage hepatocellular carcinoma patients
    Caihua Zhu
    Bing Dai
    Hua Zhan
    Ruoyu Deng
    Irish Journal of Medical Science (1971 -), 2023, 192 (3): : 1065 - 1071
  • [26] Treatment Duration of Adjuvant Immune Checkpoint Inhibitors in Hepatocellular Carcinoma Patients at High Risk of Recurrence after Resection: A Prospective, Multicentric Cohort Study
    Su, Jia-Yong
    Liu, Shao-Ping
    Xu, Xiao-Ling
    Ou, Jun-Jie
    Ye, Po-Hua
    Zhao, Bin-Tong
    Chen, Jia-Song
    Luo, Qiu-Mei
    Liu, Jin-Rong
    Tang, Fei-Min
    Li, Jian-Rong
    Yang, Da-Long
    Deng, Zhu-Jian
    Pan, Li-Xin
    Li, Yao-Jie
    Li, Le
    Qin, Zhen-Ming
    Liang, Xiu-Mei
    Ma, Yi-Li
    Ma, Liang
    Zhong, Jian-Hong
    LIVER CANCER, 2024,
  • [27] Interim efficacy and safety of PD-1 inhibitors in preventing recurrence of hepatocellular carcinoma after interventional therapy
    Qiao, Wenying
    Wang, Qi
    Hu, Caixia
    Zhang, Yinghua
    Li, Jianjun
    Sun, Yu
    Yuan, Chunwang
    Wang, Wen
    Liu, Biyu
    Zhang, Yonghong
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [28] Efficacy and safety of anlotinib as an adjuvant therapy in hepatocellular carcinoma patients with a high risk of postoperative recurrence
    Jianguo Wang
    Xiaonan Xiang
    Zhixiong Shi
    Hui Zhang
    Quanbao Zhang
    Zhikun Liu
    Guangjie Zhao
    Chuanxing Wu
    Qiang Wei
    Lin Zhong
    Zhengxin Wang
    Guoyue Lv
    Shusen Zheng
    Xiao Xu
    ChineseJournalofCancerResearch, 2023, 35 (04) : 399 - 407
  • [29] Efficacy and safety of anlotinib as an adjuvant therapy in hepatocellular carcinoma patients with a high risk of postoperative recurrence
    Wang, Jianguo
    Xiang, Xiaonan
    Shi, Zhixiong
    Zhang, Hui
    Zhang, Quanbao
    Liu, Zhikun
    Zhao, Guangjie
    Wu, Chuanxing
    Wei, Qiang
    Zhong, Lin
    Wang, Zhengxin
    Lv, Guoyue
    Zheng, Shusen
    Xu, Xiao
    CHINESE JOURNAL OF CANCER RESEARCH, 2023, 35 (04) : 399 - 407
  • [30] Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy
    Wei Chen
    Shuifang Hu
    Zelong Liu
    Yukun Sun
    Jian Wu
    Shunli Shen
    Zhenwei Peng
    Hepatology International, 2023, 17 : 406 - 416
12345